Mark Wickens
Impact in
- Oncology top 1%
- PARP inhibition in cancer therapy
- Cancer Research top 2%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 4
- PARP inhibition in cancer therapy 3
-
- Antiplatelet Therapy and Cardiovascular Diseases 3
- Heart Failure Treatment and Management 1
- Co-authors
- James Carmichael (3 shared papers)Michael Leonard Friedlander (3 shared papers)Rita Katharina Schmutzler (2 shared papers)M. William Audeh (2 shared papers)Andrew N.J. Tutt (2 shared papers)Jeffrey N. Weitzel (2 shared papers)Ursula A. Matulonis (2 shared papers)Katherine M. Bell‐McGuinn (2 shared papers)
- Journals
- The Lancet (2 papers)European Heart Journal (2 papers)Platelets (1 paper)British Journal of Clinical Pharmacology (1 paper)Journal of the American College of Cardiology (1 paper)
- Partner nations
- United KingdomUnited StatesSweden
In The Last Decade
Mark Wickens
12 papers receiving 4.9k citations
Mark Wickens's Hit Papers
Peers
Comparison fields: 5 of 87
- Oncology 1.9k
- Cancer Research 691
- Cardiology and Cardiovascular Medicine 1.1k
- Genetics 815
- Reproductive Medicine 285
Countries citing papers authored by Mark Wickens
This map shows the geographic impact of Mark Wickens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Wickens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Wickens more than expected).
Fields of papers citing papers by Mark Wickens
This network shows the impact of papers produced by Mark Wickens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Wickens. The network helps show where Mark Wickens may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Wickens, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Hit paper breakdown → | 2010 | 1955 |
| 2 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Hit paper breakdown → | 2010 | 1453 |
| 3 | Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin Hit paper breakdown → | 2006 | 618 |
| 4 | 2011 | 408 | |
| 5 | 2007 | 407 | |
| 6 | 1995 | 106 | |
| 7 | 2009 | 51 | |
| 8 | 2000 | 34 | |
| 9 | 2010 | 32 | |
| 10 | Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with renal impairment. | 2001 | 26 |
| 11 | 2006 | 22 | |
| 12 | 2007 | 1 |
About Mark Wickens
Mark Wickens is a scholar working on Oncology, Cardiology and Cardiovascular Medicine, Anesthesiology and Pain Medicine, Pharmacology and Pharmacology, having authored 12 papers that have together received 5.1k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (3 papers), Antiplatelet Therapy and Cardiovascular Diseases (3 papers), Anesthesia and Pain Management (2 papers), Pharmacogenetics and Drug Metabolism (1 paper), Alcohol Consumption and Health Effects (1 paper), Pharmacology and Obesity Treatment (1 paper), Heart Failure Treatment and Management (1 paper) and Substance Abuse Treatment and Outcomes (1 paper). The work is most often cited by research in Oncology (1.9k citations), Cancer Research (691 citations), Cardiology and Cardiovascular Medicine (1.1k citations), Genetics (815 citations) and Reproductive Medicine (285 citations). Mark Wickens has collaborated with scholars based in United Kingdom, United States and Sweden. Frequent co-authors include James Carmichael, Michael Leonard Friedlander, Rita Katharina Schmutzler, M. William Audeh, Andrew N.J. Tutt, Jeffrey N. Weitzel, Ursula A. Matulonis, Katherine M. Bell‐McGuinn, Steen Husted and Håkan Emanuelsson. Their work appears in journals such as The Lancet, European Heart Journal, Platelets, British Journal of Clinical Pharmacology and Journal of the American College of Cardiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.